Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.79
-0.0500-0.64%
Post-market: 7.78-0.0103-0.13%19:59 EDT
Volume:7.62M
Turnover:59.32M
Market Cap:8.26B
PE:-7.88
High:7.95
Open:7.85
Low:7.60
Close:7.84
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.99
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-7.89
PE(LYR):-20.39

Loading ...

ImmunityBio Inc. publishes investor presentation on ANKTIVA bladder cancer program and global regulatory approvals

Reuters
·
Mar 11

Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge

Simply Wall St.
·
Mar 10

Moderately bullish activity in ImmunityBio with shares down 5.71%

TIPRANKS
·
Mar 10

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 10

ImmunityBio Resubmits Supplemental Biologics License Application for Cancer Treatment Anktiva

MT Newswires Live
·
Mar 09

ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG

TIPRANKS
·
Mar 09

FDA acknowledges receipt of ImmunityBio’s resubmitted sBLA for ANKTIVA plus BCG in NMIBC papillary tumors

Reuters
·
Mar 09

Immunitybio Announces Resubmission of Supplemental Bla to the FDA for Anktiva® Plus Bcg in Bcg-Unresponsive Nmibc With Papillary Disease Following Agency Review of Additional Data

THOMSON REUTERS
·
Mar 09

Immunitybio Inc - Resubmits Sbla After FDA Requests Additional Data; No New Trials Required

THOMSON REUTERS
·
Mar 09

Immunitybio Inc: FDA Has Acknowledged Receipt of Resubmitted Filing

THOMSON REUTERS
·
Mar 09

Mixed options sentiment in ImmunityBio with shares down 10.25%

TIPRANKS
·
Mar 05

ImmunityBio price target raised to $12 from $7 at Piper Sandler

TIPRANKS
·
Mar 04

Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement

Stock Track
·
Feb 28

ImmunityBio Inc. Updates Financial Calendar

Reuters
·
Feb 27

Immunitybio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

THOMSON REUTERS
·
Feb 27

Stock Track | ImmunityBio Soars 5.14% in Pre-Market on Positive ANKTIVA Trial Results and Regulatory Progress

Stock Track
·
Feb 26

Immunitybio Inc: Anticipates Submitting a Biologics License Application (Bla) to U.S. FDA by Q4 2026

THOMSON REUTERS
·
Feb 26

Immunitybio Completes Enrollment in Pivotal Randomized Trial Evaluating Anktiva® Plus Bcg Versus Bcg Alone in Bcg-NaÏVe Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

THOMSON REUTERS
·
Feb 26

ImmunityBio completes enrollment in ANKTIVA plus BCG bladder cancer trial

Reuters
·
Feb 26

Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge

Stock Track
·
Feb 26